Study of Natural Killer Cells in Bone Marrow and Blood Samples From Patients With and Without Hematologic Cancer
NCT ID: NCT00918658
Last Updated: 2015-10-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
34 participants
OBSERVATIONAL
2008-04-30
2011-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This research study is looking at natural killer cells in bone marrow and blood samples from patients with hematologic cancer and from patients who do not have cancer.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of Autologous Natural Killer Cell Activity in Primary Cancer Cell Cultures
NCT05869994
Collecting and Storing Blood Samples From Patients With Cancer
NCT00900120
Collection of Blood, Bone Marrow, Tumor, or Tissue Samples From Patients With Cancer to Study Drug Resistance
NCT00026663
S9910, Collecting and Storing Blood and Bone Marrow Samples From Patients With Hematologic Cancer
NCT00919425
Collection of Blood and/or Bone Marrow for Investigation and Characterization of Normal and Abnormal Cell Growth
NCT01174615
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* To collect normal and malignant cells in bone marrow and peripheral blood samples from patients with acute myeloid leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, or multiple myeloma and from patients with no malignancy to use as target cells in cytotoxicity assays.
* To collect information about HLA type and immunophenotype of malignant cells as determined by clinical flow cytometry.
OUTLINE: Bone marrow aspirates and/or peripheral blood samples are collected and used as target cells in standard cytotoxicity assays, with notch-induced natural killer (N-NK) cells as the effector cells, to determine whether N-NK cells are capable of killing malignant cells and/or non-malignant cells. Receptor-blocking antibodies may be added to determine which NK cell receptors are responsible for malignant cell recognition and killing.
Information about HLA type and immunophenotype of the malignant cells is collected from the patient's medical record.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients with hematologic cancer
Patients with acute myeloid leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, or multiple myeloma
biologic sample preservation procedure
All specimens will be collected using the Pathology Residual Tissue Procurement.
immunologic technique
Information about HLA type and immunophenotype of the malignant cells is collected from the patient's medical record.
laboratory biomarker analysis
Bone marrow aspirates and/or peripheral blood samples are collected and used as target cells in standard cytotoxicity assays, with notch-induced natural killer (N-NK) cells as the effector cells, to determine whether N-NK cells are capable of killing malignant cells and/or non-malignant cells. Receptor-blocking antibodies may be added to determine which NK cell receptors are responsible for malignant cell recognition and killing.
Patients without cancer
Patients who do not have cancer.
biologic sample preservation procedure
All specimens will be collected using the Pathology Residual Tissue Procurement.
immunologic technique
Information about HLA type and immunophenotype of the malignant cells is collected from the patient's medical record.
laboratory biomarker analysis
Bone marrow aspirates and/or peripheral blood samples are collected and used as target cells in standard cytotoxicity assays, with notch-induced natural killer (N-NK) cells as the effector cells, to determine whether N-NK cells are capable of killing malignant cells and/or non-malignant cells. Receptor-blocking antibodies may be added to determine which NK cell receptors are responsible for malignant cell recognition and killing.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
biologic sample preservation procedure
All specimens will be collected using the Pathology Residual Tissue Procurement.
immunologic technique
Information about HLA type and immunophenotype of the malignant cells is collected from the patient's medical record.
laboratory biomarker analysis
Bone marrow aspirates and/or peripheral blood samples are collected and used as target cells in standard cytotoxicity assays, with notch-induced natural killer (N-NK) cells as the effector cells, to determine whether N-NK cells are capable of killing malignant cells and/or non-malignant cells. Receptor-blocking antibodies may be added to determine which NK cell receptors are responsible for malignant cell recognition and killing.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Meets one of the following criteria:
* No evidence of malignancy
* Diagnosis of one of the following:
* Acute myeloid leukemia
* Acute lymphoblastic leukemia
* Chronic myelogenous leukemia
* Multiple myeloma
PATIENT CHARACTERISTICS:
* Not specified
PRIOR CONCURRENT THERAPY:
* Not specified
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Case Comprehensive Cancer Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Rose Beck, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center
Cleveland, Ohio, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CASE2Z08
Identifier Type: OTHER
Identifier Source: secondary_id
CASE-2Z08-CC502
Identifier Type: OTHER
Identifier Source: secondary_id
CASE2Z08
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.